Based on data from 6 studies, predictors of HD or HF included male gender, older age, higher bilirubin, higher composite ALT and Fib-4 scores, presence of liver fibrosis (higher Fib-4 end-of-treatment [EOT] scores), presence of liver cirrhosis, prior HD or HF, and tenofovir (vs ETV) as type of discontinued NA therapy.12 This evidence concerns the gene GPT and hydrops fetalis.